Mangoceuticals, Inc. MGRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.34% | -71.83% | -137.11% | -112.55% | -55.63% |
| Total Depreciation and Amortization | -45.51% | 40.38% | 135.69% | 12,386.25% | 3,689.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -200.00% | -200.00% |
| Total Other Non-Cash Items | 36.39% | 195.36% | 395.00% | 357.87% | 173.64% |
| Change in Net Operating Assets | 409.10% | 912.80% | 42.14% | -127.61% | -47.37% |
| Cash from Operations | 33.22% | 20.51% | -20.28% | -8.66% | 2.51% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Issued | -78.68% | 980.00% | 350.00% | 200.00% | 200.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13.32% | 143.83% | 404.58% | 196.75% | 105.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -100.00% | -100.00% | -56.60% | -31.11% | 53.33% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -26.04% | -18.87% | 76.12% | 50.03% | 57.37% |
| Foreign Exchange rate Adjustments | -277.78% | 59.09% | 171.72% | 76.47% | 25.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 132.80% | 60.56% | 309.83% | 135.03% | 84.16% |